Shen Xiaoyan, Hong Myoung-Soon, Moss Joel, Vaughan Martha
Pulmonary-Critical Care Medicine Branch, Laboratory of Cell Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1230-5. doi: 10.1073/pnas.0610535104. Epub 2007 Jan 16.
Glycosylation of beta1 integrin (beta1) in the Golgi complex has been related to its function in multiple cell processes, e.g., invasiveness, matrix adhesion, and migration. Brefeldin A-inhibited guanine nucleotide-exchange proteins (BIG) 1 and BIG2 activate human ADP-ribosylation factors (ARF) 1 and ARF3 by catalyzing the replacement of ARF-bound GDP with GTP to regulate Golgi vesicular transport. We show here a requirement for BIG1 (but not BIG2) in glycosylation and function of beta1. In HepG2 cells treated for 48 or 72 h with BIG1, but not BIG2, siRNA, both the amount and electrophoretic mobility of the initially 130-kDa beta1 were increased. BIG1 content had risen by 48 h after removal of BIG1 siRNA, and the faster-migrating, aberrant 130-kDa beta1 was not seen. Peptide N-glycosidase F, but not endoglycosidase H, digestion converted all beta1 to an approximately 85-kDa (core protein) form. By electron microscopy, Golgi membranes in BIG1-depleted cells were less sharply defined than those in mock or BIG2 siRNA-treated cells, with more vesicle-like structures at the transface. Amounts of active RhoA-GTP also were decreased in such cells and restored by overexpression of HA-BIG1. Aberrant beta1 was present on the cell surface, but its function in cell spreading, adhesion, and migration was impaired. By immunofluorescence microscopy, BIG1 siRNA-treated cells showed less spreading and concentration of beta1 at the cell surface. These results indicate a previously unrecognized role for BIG1 in the glycosylation of beta1 by Golgi enzymes, which is critical for its function in developmental and other vital cell processes.
β1整合素(β1)在高尔基体复合体中的糖基化作用与其在多种细胞过程中的功能相关,例如侵袭性、基质粘附和迁移。布雷菲德菌素A抑制的鸟嘌呤核苷酸交换蛋白(BIG)1和BIG2通过催化用GTP取代与ARF结合的GDP来激活人ADP核糖基化因子(ARF)1和ARF3,从而调节高尔基体囊泡运输。我们在此表明,BIG1(而非BIG2)对于β1的糖基化和功能是必需的。在用BIG1而非BIG2的小干扰RNA(siRNA)处理48或72小时的HepG2细胞中,最初130 kDa的β1的量和电泳迁移率均增加。去除BIG1 siRNA后48小时,BIG1含量升高,且未观察到迁移速度更快的异常130 kDa的β1。肽N - 糖苷酶F而非内切糖苷酶H的消化将所有β1转化为约85 kDa(核心蛋白)形式。通过电子显微镜观察,与模拟或BIG2 siRNA处理的细胞相比,BIG1缺失细胞中的高尔基体膜边界不那么清晰,在反面有更多囊泡样结构。此类细胞中活性RhoA - GTP的量也减少,并通过HA - BIG1的过表达得以恢复。异常的β1存在于细胞表面,但其在细胞铺展、粘附和迁移中的功能受损。通过免疫荧光显微镜观察,BIG1 siRNA处理的细胞在细胞表面显示出较少的β1铺展和聚集。这些结果表明,BIG1在高尔基体酶对β1的糖基化中具有先前未被认识到的作用,这对于其在发育和其他重要细胞过程中的功能至关重要。